Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Multiple Myeloma 4Neoplasms 3Lymphoma 3Leukemia 2Prostatic Neoplasms 1Neoplasms, Plasma Cell 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × plitidepsin × Clear all
NCT03070964 2020-10-14

A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

PharmaMar

Phase 2 Terminated
14 enrolled 21 charts
Lymphoid

Lymphoma

NCT00884286 2018-04-25

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

PharmaMar

Phase 2 Completed
67 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT00788099 2011-06-07

Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas

PharmaMar

Phase 1 Completed
45 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡